Drugs and patents in ATC class C01

Last updated: February 19, 2026

This report details the patent landscape for cardiac therapy drugs (ATC Class C01), focusing on key therapeutic areas, prevalent patent strategies, and emerging technological trends. Analysis reveals concentrated patent activity in heart failure and hypertension, with a growing focus on novel mechanisms of action and combination therapies. The patent expiry profile indicates a significant number of patents for established treatments expiring in the next five years, presenting opportunities for generic competition and the introduction of next-generation therapies.

What are the Primary Therapeutic Areas within Cardiac Therapy (C01)?

Cardiac therapy (ATC Class C01) encompasses a range of drugs targeting the cardiovascular system. The primary therapeutic areas are:

Heart Failure: Drugs designed to improve the heart's pumping function, manage fluid retention, and reduce cardiac workload. This includes positive inotropic agents, diuretics, and vasodilators.
Hypertension: Medications used to lower blood pressure. This broad category includes ACE inhibitors, angiotensin II receptor blockers (ARBs), calcium channel blockers, beta-blockers, and diuretics.
Arrhythmias: Antiarrhythmic drugs that correct irregular heart rhythms. These are classified based on their mechanism of action (e.g., Class I to Class IV).
Angina Pectoris: Treatments for chest pain caused by reduced blood flow to the heart. This includes nitrates, calcium channel blockers, and beta-blockers.
Antithrombotic Agents (Cardiac Specific): While some antithrombotics have broader indications, specific formulations or targets relevant to cardiac conditions are considered. This includes antiplatelet agents and anticoagulants used to prevent blood clots in cardiac patients.
Cholesterol-Lowering Agents (Cardiac Focus): Drugs primarily used to manage hyperlipidemia, a significant risk factor for cardiovascular disease. Statins are the most prominent class.

What are the Dominant Patenting Strategies for Cardiac Therapy Drugs?

Patenting strategies in cardiac therapy drugs are multifaceted, aiming to protect existing market share and establish new intellectual property. Key strategies include:

New Chemical Entity (NCE) Patents: These are fundamental patents protecting the core molecule. The lifespan of these patents dictates the period of market exclusivity. For example, patents for novel ARNI (Angiotensin Receptor-Neprilysin Inhibitor) drugs have been critical for market entry.
Formulation Patents: Protecting specific drug delivery systems, such as extended-release formulations, new salt forms, or combinations of existing drugs. For instance, patented sustained-release formulations of beta-blockers have extended market exclusivity.
Method of Treatment Patents: Protecting specific uses of a drug for particular patient populations or indications. This can include patenting the use of a known drug for a new cardiac condition or a specific stage of heart disease.
Polymorph Patents: Protecting specific crystalline forms of an active pharmaceutical ingredient (API), which can affect drug stability, bioavailability, and manufacturing processes.
Combination Therapy Patents: Protecting novel combinations of two or more existing drugs to achieve synergistic therapeutic effects or improve patient compliance. The development of fixed-dose combination antihypertensives has been a significant area for these patents.
Patents on Manufacturing Processes: Protecting novel or improved methods for synthesizing the drug API, which can confer a competitive advantage.

Which Therapeutic Sub-Classes Within C01 Have the Highest Patenting Activity?

Patent filing activity is not uniform across C01. Specific sub-classes show higher levels of innovation and patent protection:

Heart Failure (C01B, C01E, C01F): This sub-class, encompassing agents for heart failure and circulatory stimulants, consistently shows high patenting activity. The introduction of novel mechanisms like ARNI (sacubitril/valsartan) and SGLT2 inhibitors for heart failure has driven significant patent filings.
Hypertension (C01A, C01C, C01D): Antihypertensive agents remain a core area. While many first-generation drugs are off-patent, innovation continues in fixed-dose combinations, novel formulations of existing drugs, and therapies targeting new pathways like the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system modulators.
Agents Affecting Blood Lipids (C01B): While broader than just cardiac, cholesterol-lowering agents, particularly statins and newer PCSK9 inhibitors, have seen substantial patenting activity due to their critical role in preventing cardiovascular events.

What is the Patent Expiry Profile for Key Cardiac Therapy Drugs?

The patent expiry profile indicates periods of significant market transition.

Drug Class/Example	Generic Name(s)	Original Patent Expiry (Approximate)	Key Marketed Products (Examples)
Angiotensin Receptor Blockers (ARBs)	Losartan	2010	Cozaar, Hyzaar
	Valsartan	2012	Diovan, Exforge
	Olmesartan	2016	Benicar, Tribenzor
Angiotensin-Converting Enzyme Inhibitors (ACEIs)	Enalapril	2000	Vasotec, Vaseretic
	Lisinopril	2002	Prinivil, Zestril
Beta-Blockers	Metoprolol	2005	Lopressor, Toprol XL
	Atenolol	2001	Tenormin
Calcium Channel Blockers (Dihydropyridines)	Amlodipine	2007	Norvasc
	Nifedipine	2004	Procardia, Adalat
Angiotensin Receptor-Neprilysin Inhibitors (ARNIs)	Sacubitril/Valsartan	2026 (US)	Entresto
SGLT2 Inhibitors (for Heart Failure)	Dapagliflozin	2029 (US)	Farxiga (also diabetes)
	Empagliflozin	2031 (US)	Jardiance (also diabetes)
PCSK9 Inhibitors	Evolocumab	2029 (US)	Repatha
	Alirocumab	2030 (US)	Praluent

Note: Patent expiry dates are approximate and can vary significantly based on jurisdiction, patent extensions (e.g., Hatch-Waxman), and specific patents covering formulations or methods of use. This table focuses on primary active ingredient patents.

The period between 2025 and 2031 represents a crucial window for several blockbuster cardiac therapies, including ARNIs and established SGLT2 inhibitors when their primary patent protection is set to expire. This will likely lead to increased generic competition for these latter-stage treatments.

What are the Emerging Technologies and Patent Trends in Cardiac Therapy?

Innovation in cardiac therapy is increasingly driven by novel mechanisms of action and advanced therapeutic modalities:

Gene and Cell Therapies: While still nascent for broad cardiac application, early-stage patent filings are emerging for gene editing techniques and cell-based regenerative approaches for repairing damaged heart tissue. These often involve patents on viral vectors, delivery systems, and specific genetic sequences.
Targeting Novel Biomarkers and Pathways: Beyond RAAS and sympathetic modulation, research is progressing on drugs targeting inflammatory pathways (e.g., NLRP3 inflammasome), metabolic pathways (e.g., AMPK activators), and novel signaling cascades implicated in cardiac remodeling and dysfunction. Patents in this area are typically focused on small molecules or biologics against these specific targets.
Personalized Medicine and Diagnostics: Patents are increasingly linked to companion diagnostics or predictive biomarkers that identify patient subgroups most likely to respond to specific therapies. This includes patents on genetic tests or protein assays used in conjunction with a drug.
Wearable Technology and Digital Health Integration: While not direct drug patents, there is an increasing intersection of drug delivery and monitoring. Patents may cover drug delivery devices integrated with biosensors or systems that use wearable data to optimize drug dosing for chronic cardiac conditions.
Advanced Delivery Systems: Beyond simple extended-release, innovation includes targeted drug delivery to the heart muscle, implantable devices that release therapeutic agents, and nanoparticle-based delivery systems.

What is the Competitive Landscape and Market Concentration for Key Cardiac Therapy Segments?

The competitive landscape varies by cardiac therapy segment:

Antihypertensives: This market is highly consolidated with generic penetration. Major players often focus on fixed-dose combinations and life-cycle management of established brands. Key players include Novartis, Pfizer, AstraZeneca, and Merck.
Heart Failure: Historically dominated by diuretics and older inotropes, this segment has seen significant disruption from ARNIs and SGLT2 inhibitors. Novartis (Entresto) and AstraZeneca/Eli Lilly (Farxiga/Jardiance) are major innovators. The market is increasingly competitive with the anticipation of generic entry for these newer classes.
Lipid-Lowering Agents: Statins are largely generic. The market for PCSK9 inhibitors (Regeneron/Sanofi and Amgen) is newer and has patent exclusivity, but faces pricing pressures and competition from biosimil/generic development in the longer term.
Antiarrhythmics: This segment is fragmented, with many drugs having expired patents. Innovation is slower and often focuses on specific subclasses or improved formulations for niche indications.

The market is characterized by a mature generic sector for older drugs and intense R&D focus on newer therapies for heart failure and dyslipidemia.

Key Takeaways

Patent protection for cardiac therapy drugs centers on novel chemical entities, formulations, and methods of use.
Heart failure and hypertension are the most active patenting areas, driven by significant unmet needs and the introduction of novel drug classes.
The patent expiry profile for several blockbuster cardiac drugs, including ARNIs and SGLT2 inhibitors, is approaching between 2025 and 2031, signaling significant market shifts and generic opportunities.
Emerging technological trends include gene and cell therapies, personalized medicine, and novel drug delivery systems, which are increasingly represented in the patent landscape.
The competitive landscape is bifurcated, with a highly genericized antihypertensive market and a more innovation-driven market for heart failure and lipid-lowering therapies.

Frequently Asked Questions

Which specific patents are most critical for protecting novel heart failure therapies like ARNIs? The most critical patents for ARNIs like sacubitril/valsartan (Entresto) are those covering the combined compound itself, specific polymorphic forms, and novel pharmaceutical compositions or formulations designed to optimize bioavailability and patient adherence. Method of treatment patents for specific patient populations with heart failure also play a key role.
How are patent strategies adapting to the rise of digital health in cardiac therapy? Patent strategies are evolving to encompass integrated systems. This includes patents on drug delivery devices that incorporate sensors, software algorithms that analyze patient data (e.g., from wearables) to adjust dosing, and platforms for remote patient monitoring that are linked to specific drug regimens.
What are the typical patent lengths for combination cardiac therapies compared to single-agent drugs? Combination therapies may receive separate patents for the fixed-dose formulation or the synergistic effect of the combination, which can extend market exclusivity beyond the expiry of the individual drug patents. However, the underlying active ingredients are still subject to their original patent timelines.
Are there significant patent disputes ongoing in the cardiac therapy space? Yes, patent disputes are common, particularly concerning generic challenges to secondary patents (formulations, methods of use) after the primary compound patent has expired. These disputes often involve complex litigation around patent validity and infringement, especially for high-value drugs.
What is the role of biologics and biosimil/generic development in the C01 patent landscape? While many cardiac therapies are small molecules, biologics like PCSK9 inhibitors have introduced new patenting dynamics. The development of biosimil/generic versions of these biologics will follow patent expiry, similar to small molecule generics, but with a distinct regulatory pathway and potentially different patent litigation strategies.

Citations

[1] World Health Organization. (2023). Anatomical Therapeutic Chemical (ATC) Classification Index. Retrieved from https://www.whocc.no/atc_classification/ [2] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations [3] European Medicines Agency. (n.d.). Medicines. Retrieved from https://www.ema.europa.eu/en/medicines [4] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from https://www.uspto.gov/patents/search [5] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/patent/search/advanced

Drugs in ATC Class C01

Subclasses in ATC: C01 - CARDIAC THERAPY

Cardiac Therapy (ATC Class C01) Patent Landscape Analysis